A global profile of gene promoter methylation in treatment-naïve urothelial cancer

The epigenetic alteration of aberrant hypermethylation in the promoter CpG island of a gene is associated with repression of transcription. In neoplastic cells, aberrant hypermethylation is well described as a mechanism of allele inactivation of particular genes with a tumor suppressor function. To investigate the role of aberrant hypermethylation in the biology and progression of urothelial cancer, we examined 101 urothelial (transitional cell) carcinomas (UC), broadly representative of the disease at presentation, with no prior immunotherapy, chemotherapy or radiotherapy, by Infinium HM27 containing 14,495 genes. The genome-wide signature of aberrant promoter hypermethylation in UC consisted of 729 genes significant by a Wilcoxon test, hypermethylated in a CpG island within 1 kb of the transcriptional start site and unmethylated in normal urothelium from aged individuals. We examined differences in gene methylation between the two main groups of UC: the 75% that are superficial, which often recur but rarely progress, and the 25% with muscle invasion and poor prognosis. We further examined pairwise comparisons of the pathologic subgroups of high or low grade, invasive or non-invasive (pTa), and high grade superficial or low grade superficial UC. Pathways analysis indicated over-representation of genes involved in cell adhesion or metabolism in muscle-invasive UC. Notably, the TET2 epigenetic regulator was one of only two genes more frequently methylated in superficial tumors and the sole gene in low grade UC. Other chromatin remodeling genes, MLL3 and ACTL6B, also showed aberrant hypermethylation. The Infinium methylation value for representative genes was verified by pyrosequencing. An available mRNA expression data set indicated many of the hypermethylated genes of interest to be downregulated in UC. Unsupervised clustering of the most differentially methylated genes distinguished muscle invasive from superficial UC. After filtering, cluster analysis showed a CpG Island Methylator Phenotype (CIMP)-like pattern of widespread methylation in 11 (11%) tumors. Nine of these 11 tumors had hypermethylation of TET2. Our analysis provides a basis for further studies of hypermethylation in the development and progression of UC.

[1]  R. Henrique,et al.  Epigenetic biomarkers in urological tumors: A systematic review. , 2014, Cancer letters.

[2]  R. Uzzo,et al.  Genome-Wide Promoter Methylome of Small Renal Masses , 2013, PloS one.

[3]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[4]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[5]  Nancy Papalopulu,et al.  Inositol kinase and its product accelerate wound healing by modulating calcium levels, Rho GTPases, and F-actin assembly , 2013, Proceedings of the National Academy of Sciences.

[6]  I. Tomlinson,et al.  Whole-genome methylation analysis of benign and malignant colorectal tumours , 2013, The Journal of pathology.

[7]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[8]  A. McCullough.  Comprehensive genomic characterization of squamous cell lung cancers , 2013 .

[9]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[10]  M. Peinado,et al.  Evaluation of single CpG sites as proxies of CpG island methylation states at the genome scale , 2012, Nucleic acids research.

[11]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[12]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[13]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[14]  R. Stam,et al.  Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. , 2012, European urology.

[15]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[16]  P. Laird,et al.  Genome-scale analysis of aberrant DNA methylation in colorectal cancer. , 2012, Genome research.

[17]  Huanming Yang,et al.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.

[18]  M. Toyota,et al.  Frequent Alteration of MLL3 Frameshift Mutations in Microsatellite Deficient Colorectal Cancer , 2011, PloS one.

[19]  Carsten Wiuf,et al.  Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers , 2011, Clinical Cancer Research.

[20]  L. Mariani,et al.  TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations , 2011, Journal of Clinical Pathology.

[21]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[22]  Wei Zhang,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[23]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[24]  P. Cairns,et al.  Epigenetics of kidney cancer and bladder cancer. , 2011, Epigenomics.

[25]  Huanming Yang,et al.  The DNA Methylome of Human Peripheral Blood Mononuclear Cells , 2010, PLoS biology.

[26]  Peter A. Jones,et al.  Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. , 2010, Cancer research.

[27]  P. Cairns,et al.  Signaling pathways in renal cell carcinoma , 2010, Cancer biology & therapy.

[28]  Patrick Pauwels,et al.  Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination , 2010, PloS one.

[29]  B. Christensen,et al.  Identification of Methylated Genes Associated with Aggressive Bladder Cancer , 2010, PloS one.

[30]  Jingqin Luo,et al.  Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. , 2010, Gynecologic oncology.

[31]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[32]  Young Yang,et al.  The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma , 2010, Molecular Cancer.

[33]  Kimberly D Siegmund,et al.  Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns. , 2009, Human molecular genetics.

[34]  K. Gunderson,et al.  Genome-wide DNA methylation profiling using Infinium® assay. , 2009, Epigenomics.

[35]  Geoffrey S. Tobias,et al.  Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer , 2009, Nature Genetics.

[36]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[37]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[38]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[39]  M. Toyota,et al.  Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. , 2008, Cancer research.

[40]  B. Karlan,et al.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.

[41]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[42]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[43]  M. Esteller,et al.  Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays , 2007, British Journal of Cancer.

[44]  Liang Da,et al.  CpG methylation plays a vital role in determining tissue- and cell-specific expression of the human cell-death-inducing DFF45-like effector A gene through the regulation of Sp1/Sp3 binding , 2007, Nucleic acids research.

[45]  Paul Cairns,et al.  Gene methylation and early detection of genitourinary cancer: the road ahead , 2007, Nature Reviews Cancer.

[46]  K. Aldape,et al.  Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth , 2007, Proceedings of the National Academy of Sciences.

[47]  M. Ruonala,et al.  Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147. , 2007, Molecular biology of the cell.

[48]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[49]  J. Rogers,et al.  DNA methylation profiling of human chromosomes 6, 20 and 22 , 2006, Nature Genetics.

[50]  A. Fleig,et al.  TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. , 2006, Cellular signalling.

[51]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[52]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[53]  Carlos Cordon-Cardo,et al.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  K. Aldape,et al.  The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration , 2006, Cancer biology & therapy.

[55]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[56]  S. Hirohashi,et al.  Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene , 2005, Laboratory Investigation.

[57]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[58]  R. Uzzo,et al.  Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel , 2004, Clinical Cancer Research.

[59]  A. Starzinski-Powitz,et al.  Novel membrane protein shrew-1 targets to cadherin-mediated junctions in polarized epithelial cells. , 2003, Molecular biology of the cell.

[60]  A. Marx,et al.  World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .

[61]  G. Crabtree,et al.  Identification of a polymorphic, neuron-specific chromatin remodeling complex. , 2002, Genes & development.

[62]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[63]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[64]  S. Chen,et al.  CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor , 1998, The EMBO journal.

[65]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[66]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.